DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 101–200 of 1,056
Machine Learning for Drug-Target Interaction Prediction
Chen, R., Liu, X., Jin, S., Lin, J., & Liu, J. (2018) · Molecules · doi:10.3390/molecules23092208 · Cited by 292
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
“Xie et al. applied a supervised deep neural network (DNN) to L1000 gene expression data and a drug-target interaction activity dataset from DrugBank (78) and accurately predicted established drug-target pairs using external validation sets (79) (84) with the potential to be repurposed for poor-prognosis CNS cancers su…”
MethodMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 133
Advancing the use of genome-wide association studies for drug repurposing
Reay, W. R., & Cairns, M. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00387-z · Cited by 283
Cyclobutanes in Small‐Molecule Drug Candidates
van der Kolk, M. R., Janssen, M. A. C. H., Rutjes, F. P. J. T., & Blanco‐Ania, D. (2022) · ChemMedChem · doi:10.1002/cmdc.202200020 · Cited by 274
Biological network analysis with deep learning
Muzio, G., O’Bray, L., & Borgwardt, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa257 · Cited by 248
“…Tox21 [37] Benchmark dataset of compounds & their toxicity on some biological targets [33] http://graphlearning.io/ DrugBank [38], [39] Database of drug structure, drug-target information and DDIs [25], [40], [27], [41], [28] https://www.drugbank.ca DDI Networks Twosides [42]…”
Quantifying genetic effects on disease mediated by assayed gene expression levels
Yao, D. W., O’Connor, L. J., Price, A. L., & Gusev, A. (2020) · Nature Genetics · doi:10.1038/s41588-020-0625-2 · Cited by 298
Discovery and development of safe-in-man broad-spectrum antiviral agents
Andersen, P. I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjørås, M., Telling, K., Lutsar, I., Dumpis, U., Irie, Y., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.018 · Cited by 280
Yan, Y., Shin, W. I., Pang, Y. X., Meng, Y., Lai, J., You, C., Zhao, H., Lester, E., Wu, T., & Pang, C. H. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072323 · Cited by 266
“Ganciclovir is first converted to its active form, monophosphate, whilst being catalyzed by a virus-coded cellular enzyme known as thymidine kinase (TK) [71].”
BackgroundPotential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Lin, J., Zhou, J., & Xu, Y. (2023) · Brain · doi:10.1093/brain/awad070 · Cited by 271
“27 We also searched current medications targeting the identified potential causal proteins.”
Transformers and large language models in healthcare: A review
Nerella, S., Bandyopadhyay, S., Zhang, J., Contreras, M., Siegel, S., Bumin, A., Silva, B., Sena, J., Shickel, B., Bihorac, A., et al. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102900 · Cited by 197
“5) [434], Human Metabolome Database (HMDB) (version 4.”
InfluentialDrugComb: an integrative cancer drug combination data portal
Zagidullin, B., Aldahdooh, J., Zheng, S., Wang, W., Wang, Y., Saad, J., Malyutina, A., Jafari, M., Tanoli, Z., Pessia, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz337 · Cited by 263
“To retrieve the mechanisms of actions of the 2276 drugs in DrugComb, their chemical identifiers were queried from major databases including STITCH, PubCHEM, ChEMBL, DrugBank (33) and KEGG (34).”
MethodDeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
Wang, J., Liu, X., Shen, S., Deng, L., & Liu, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab390 · Cited by 261
Kang, J., Tang, Q., He, J., Li, L., Yang, N., Yu, S., Wang, M., Zhang, Y., Lin, J., Cui, T., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab997 · Cited by 249
“For the convenience of users, aliases, descriptions and other IDs from DrugBank (22), OMIM (23), Ensembl (24), HGNC (25), HPRD (26) and Uniprot (27) were all included in the interactor information.”
BackgroundVázquez, J., López, M., Gibert, E., Herrero, E., & Luque, F. J. (2020) · Molecules · doi:10.3390/molecules25204723 · Cited by 247
“Molecules 2020, 25, 4723 15 of 27 To facilitate this task, there has been continued progress in the availability of experimental data in the public domain during the last two decades [172], which is exemplified in the consolidation of curated databases of bioactive molecules with drug-like properties, as exemplified w…”
BackgroundMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Open access in silico tools to predict the ADMET profiling of drug candidates
Kar, S., & Leszczynski, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1798926 · Cited by 250
“admetSAR 96,000 5 physicochemical and 49 ADMET properties SMILES [87], BindingDB 1,854,767 binding data (7,493 protein targets and 820,433 small molecules) ADMET-related results found within the 1.”
BackgroundRepurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., Zhang, Z., Li, K., Karypis, G., & Cheng, F. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00316 · Cited by 257
CFM-ID 3.0: Significantly Improved ESI-MS/MS Prediction and Compound Identification
Djoumbou-Feunang, Y., Pon, A., Karu, N., Zheng, J., Li, C., Arndt, D., Gautam, M., Allen, F., & Wishart, D. S. (2019) · Metabolites · doi:10.3390/metabo9040072 · Cited by 252
Self-citationDisease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients
(DeCOI), G. C.-1. O. I., Aschenbrenner, A. C., Mouktaroudi, M., Krämer, B., Oestreich, M., Antonakos, N., Nuesch-Germano, M., Gkizeli, K., Bonaguro, L., Reusch, N., et al. (2021) · Genome Medicine · doi:10.1186/s13073-020-00823-5 · Cited by 255
“Drug target genes were identified using the DrugBank database [63] (Add-”
MethodDiscovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors
Foster, S. R., Hauser, A. S., Vedel, L., Strachan, R. T., Huang, X.-P., Gavin, A. C., Shah, S. D., Nayak, A. P., Haugaard-Kedström, L. M., Penn, R. B., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.010 · Cited by 252
“Over 85 endogenous peptide/protein-derived drugs target 51 proteins, half of which are G protein-coupled receptors (GPCRs) (Wishart et al., 2018).”
BackgroundIn Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM
Durán-Iturbide, N. A., Díaz-Eufracio, B. I., & Medina-Franco, J. L. (2020) · ACS Omega · doi:10.1021/acsomega.0c01581 · Cited by 238
The next level in chemical space navigation: going far beyond enumerable compound libraries
Hoffmann, T., & Gastreich, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.013 · Cited by 240
Liu, J., Liu, J., Tong, X., Peng, W., Wei, S., Sun, T., Wang, Y., Zhang, B., & Li, W. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s319786 · Cited by 241
A foundation model for clinician-centered drug repurposing
Huang, K., Chandak, P., Wang, Q., Havaldar, S., Vaid, A., Leskovec, J., Nadkarni, G. N., Glicksberg, B. S., Gehlenborg, N., & Zitnik, M. (2024) · Nature Medicine · doi:10.1038/s41591-024-03233-x · Cited by 249
“AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion 47 .”
BackgroundRuben, M. D., Smith, D. F., FitzGerald, G. A., & Hogenesch, J. B. (2019) · Science · doi:10.1126/science.aax7621 · Cited by 236
Muus, C., Luecken, M. D., Eraslan, G., Waghray, A., Heimberg, G., Sikkema, L., Kobayashi, Y., Vaishnav, E. D., Subramanian, A., Smilie, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.19.049254 · Cited by 236
Xia, Q., Xun, Y., Lu, J., Lu, Y., Yang, Y., Zhou, P., Hu, J., Li, C., & Wang, S. (2020) · Cell Proliferation · doi:10.1111/cpr.12949 · Cited by 241
Self-citationNetwork-Based Methods for Prediction of Drug-Target Interactions
Wu, Z., Li, W., Liu, G., & Tang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01134 · Cited by 237
“In order to overcome one of the aforementioned pitfalls that NBI cannot predict targets for new chemical entities, we proposed a new network-based method entitled substructuredrug-target network-based inference (SDTNBI) (Wu et al., 2017).”
BackgroundMethodInfluentialLiu, H., Zhang, W., Zou, B., Wang, J., Deng, Y., & Deng, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1007 · Cited by 230
Rifaioglu, A. S., Nalbat, E., Atalay, V., Martin, M. J., Cetin-Atalay, R., & Doğan, T. (2020) · Chemical Science · doi:10.1039/c9sc03414e · Cited by 240
Multi-modal molecule structure–text model for text-based retrieval and editing
Liu, S., Nie, W., Wang, C., Lu, J., Qiao, Z., Liu, L., Tang, J., Xiao, C., & Anandkumar, A. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00759-6 · Cited by 179
“Here we extract three fields in DrugBank: the description field, the pharmacodynamics field and the anatomical therapeutic chemical (ATC) field.”
InfluentialDeep learning for drug response prediction in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz171 · Cited by 237
Jia, H., Häring, A. P., Berger, F., Zhang, L., & Ritter, T. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02606 · Cited by 240
Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling
Zhao, L., Ciallella, H. L., Aleksunes, L. M., & Zhu, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.005 · Cited by 228
“…REAL Database [29], PubChem [31], and ChEMBL [30]); (ii) chemical databases designed specifically for drug/drug-like compounds (e.g., DrugBank [51], AICD [52], and e-Drug3D [53]); (iii) collections of drug targets, including genomics and proteomics data (e.g., BindingDB [54], Supertarget…”
BackgroundGenerating Multibillion Chemical Space of Readily Accessible Screening Compounds
Grygorenko, O. O., Radchenko, D. S., Dziuba, I., Chuprina, A., Gubina, K. E., & Moroz, Y. S. (2020) · iScience · doi:10.1016/j.isci.2020.101681 · Cited by 214
Machine learning applications in drug development
Réda, C., Kaufmann, E., & Delahaye-Duriez, A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.006 · Cited by 228
Accelerating antibiotic discovery through artificial intelligence
Melo, M. C. R., Maasch, J. R. M. A., & de la Fuente-Nunez, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02586-0 · Cited by 234
Li, L., Yang, L., Yang, L., He, C., He, Y., Chen, L., Dong, Q., Zhang, H., Chen, S., & Li, P. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00853-2 · Cited by 206
“…em. ncbi. nlm. nih. gov) [50], STRING (https:// string-db. org) [51], Uniprot (https: // www. unipr ot. org/) [52], Drugbank (www. drugb-ank. ca) [53], OMIM (https:// www. omim. org/) [54], GeneCards (www. genec ards. org) [55], DisGeNET (https:// www. disge net. org/ api) [56], TTD (https://…”
Bender, A., & Cortes-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.037 · Cited by 232
BitterDB: taste ligands and receptors database in 2019
Dagan-Wiener, A., Di Pizio, A., Nissim, I., Bahia, M. S., Dubovski, N., Margulis, E., & Niv, M. Y. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky974 · Cited by 226
“Finally, when available, BitterDB provides a link to the compound entry in PubChem (31), ZINC (32), DrugBank (33) and IUPHAR/BPS Guide to PHARMACOLOGY database (34).”
MethodGlobal targeting of functional tyrosines using sulfur-triazole exchange chemistry
Hahm, H. S., Toroitich, E. K., Borne, A. L., Brulet, J. W., Libby, A. H., Yuan, K., Ware, T. B., McCloud, R. L., Ciancone, A. M., & Hsu, K.-L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0404-5 · Cited by 219
A deep-learning framework for multi-level peptide–protein interaction prediction
Lei, Y., Li, S., Liu, Z., Wan, F., Tian, T., Li, S., Zhao, D., & Zeng, J. (2021) · Nature Communications · doi:10.1038/s41467-021-25772-4 · Cited by 222
Genomics of hypertension: the road to precision medicine
Padmanabhan, S., & Dominiczak, A. F. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00466-4 · Cited by 217
Thota, S., Rodrigues, D. A., Pinheiro, P. D. S. M., Lima, L. M., Fraga, C. A. M., & Barreiro, E. J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.015 · Cited by 222
Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., & Kim, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19313-8 · Cited by 212
Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study
Bitew, M., Desalegn, T., Demissie, T. B., Belayneh, A., Endale, M., & Eswaramoorthy, R. (2021) · PLOS ONE · doi:10.1371/journal.pone.0260853 · Cited by 197
Schork, A. J., Won, H., Appadurai, V., Nudel, R., Gandal, M., Delaneau, O., Revsbech Christiansen, M., Hougaard, D. M., Bækved-Hansen, M., Bybjerg-Grauholm, J., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0320-0 · Cited by 223
Protein–Ligand Docking in the Machine-Learning Era
Yang, C., Chen, E. A., & Zhang, Y. (2022) · Molecules · doi:10.3390/molecules27144568 · Cited by 188
Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer
Liu, Z., Zhao, Q., Zuo, Z.-X., Yuan, S.-Q., Yu, K., Zhang, Q., Zhang, X., Sheng, H., Ju, H.-Q., Cheng, H., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101302 · Cited by 225
Kong, X., Liu, C., Zhang, Z., Cheng, M., Mei, Z., Li, X., Liu, P., Diao, L., Ma, Y., Jiang, P., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad926 · Cited by 205
“While inheriting all known TTIs of BATMAN-TCM 1.0, we integrated known TTI datasets from multiple published databases (Figure 1 ), including the Kyoto Encyclopedia of Genes and Genomes (KEGG; 14 ), DrugBank ( 15 ), the Therapeutic Target Database (TTD; 16 ), HIT ( 9 ) and HERB ( 10 ).”
MethodInfluentialMUFFIN: multi-scale feature fusion for drug–drug interaction prediction
Chen, Y., Ma, T., Yang, X., Wang, J., Song, B., & Zeng, X. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab169 · Cited by 209
Zhou, W., Zhang, H., Wang, X., Kang, J., Guo, W., Zhou, L., Liu, H., Wang, M., Jia, R., Du, X., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2021.153837 · Cited by 210
An omics perspective on drug target discovery platforms
Paananen, J., & Fortino, V. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 207
“DrugBank [120] collects comprehensive molecular information about drugs, their mechanisms, interactions and targets.”
BackgroundTraylor, M., Persyn, E., Tomppo, L., Klasson, S., Abedi, V., Bakker, M. K., Torres, N., Li, L., Bell, S., Rutten-Jacobs, L., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00031-4 · Cited by 213
Singh, R., Sledzieski, S., Bryson, B., Cowen, L., & Berger, B. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220778120 · Cited by 196
“Wolff et al. (43) previously identified PD-166326 as a tyrosinekinase inhibitor but did not report any binding to EPHB1, and DrugBank (44) lists only ABL1 as a known target (DrugBank ID: DB08339).”
InfluentialComputational methods and tools to predict cytochrome P450 metabolism for drug discovery
Tyzack, J. D., & Kirchmair, J. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13445 · Cited by 206
“…(Simulations Plus) has functionality to both predict inhibitors for five major drug metabolizing CYPs and substrates for nine CYP isoforms using data acquired from the BIOVIA Metabolite database, (BIOVIA Metabolite, n.d.) the Drugbank database (Wishart et al., 2018), and other public resources.”
MethodGu, Y., Yu, Z., Wang, Y., Chen, L., Lou, C., Yang, C., Li, W., Liu, G., & Tang, Y. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae298 · Cited by 188
PDBe: improved findability of macromolecular structure data in the PDB
Armstrong, D. R., Berrisford, J. M., Conroy, M. J., Gutmanas, A., Anyango, S., Choudhary, P., Clark, A. R., Dana, J. M., Deshpande, M., Dunlop, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz990 · Cited by 207
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Duarte, J. M., Dutta, S., Fayazi, M., Feng, Z., et al. (2022) · Protein Science · doi:10.1002/pro.4213 · Cited by 202
“A subset of small-molecule ligands occurring in PDB structures include US FDAapproved therapeutics and investigational agents.(72) Analyses of US FDA drug approvals between 2010 and 2018 revealed (i) that open access to PDB data facilitated discovery and development of the vast majority of these new drugs,(73) and (ii…”
BackgroundYu, G., Xu, C., Zhang, D., Ju, F., & Ni, Y. (2022) · iMeta · doi:10.1002/imt2.10 · Cited by 204
“…including Kyoto Encyclopedia of Genes and Genomes (KEGG) [13], the human metabolome database (HMDB) [14], BIGG [15], and Chemical Entities of Biological Interest (ChEBI) [16], the Food Database (FoodDB) [17], Drugbank [18], and the Toxin and Toxin Target Database (T3DB) [19] (Figure 1A).”
BackgroundTowards reproducible computational drug discovery
Schaduangrat, N., Lampa, S., Simeon, S., Gleeson, M. P., Spjuth, O., & Nantasenamat, C. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-0408-x · Cited by 208
Malyutina, A., Majumder, M. M., Wang, W., Pessia, A., Heckman, C. A., & Tang, J. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006752 · Cited by 197
SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization
Yu, Y., Huang, K., Zhang, C., Glass, L. M., Sun, J., & Xiao, C. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab207 · Cited by 191
GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources
Pándy-Szekeres, G., Caroli, J., Mamyrbekov, A., Kermani, A. A., Keserű, G. M., Kooistra, A. J., & Gloriam, D. E. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1013 · Cited by 201
“The information on endogenous ligands and target FDA approval status have been derived from Guide to Pharmacology (15) and DrugBank (34) databases, respectively.”
MethodInfluentialFang, J., Zhang, P., Zhou, Y., Chiang, C.-W., Tan, J., Hou, Y., Stauffer, S., Li, L., Pieper, A. A., Cummings, J., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00138-z · Cited by 206
SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update
Licata, L., Lo Surdo, P., Iannuccelli, M., Palma, A., Micarelli, E., Perfetto, L., Peluso, D., Calderone, A., Castagnoli, L., & Cesareni, G. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz949 · Cited by 211
Multi-view Graph Contrastive Representation Learning for Drug-Drug Interaction Prediction
Wang, Y., Min, Y., Chen, X., & Wu, J. (2021) · Proceedings of the Web Conference 2021 · doi:10.1145/3442381.3449786 · Cited by 182
Liu, Q., & Xie, L. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 203
“Drug target information that is collected from databases, including DrugBank and ChEMBL [36,37], are mainly proteins that can directly associate with drugs.”
Scientific Large Language Models: A Survey on Biological & Chemical Domains
Zhang, Q., Ding, K., Lv, T., Wang, X., Yin, Q., Zhang, Y., Yu, J., Wang, Y., Li, X., Xiang, Z., et al. (2025) · ACM Computing Surveys · doi:10.1145/3715318 · Cited by 122
Sleep in the United States Military
Good, C. H., Brager, A. J., Capaldi, V. F., & Mysliwiec, V. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0431-7 · Cited by 180
“Caffeine’s half-life ranges from 3 to 7 h in adults [236], and can protect against performance decline during sleep loss in a dose[237] and time-dependent manner [238].”
BackgroundGenerative chemistry: drug discovery with deep learning generative models
Bian, Y., & Xie, X.-Q. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04674-8 · Cited by 171
DPDDI: a deep predictor for drug-drug interactions
Feng, Y.-H., Zhang, S.-W., & Shi, J.-Y. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03724-x · Cited by 196
HIT 2.0: an enhanced platform for Herbal Ingredients' Targets
Yan, D., Zheng, G., Wang, C., Chen, Z., Mao, T., Gao, J., Yan, Y., Chen, X., Ji, X., Yu, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1011 · Cited by 195
“…herbal compounds and molecular targets, the first herbal-ingredient-target database, HIT, was established in 2010 via manual curation of 1301 literature-described targets for herbal compound from 3250 literatures, with convenient links to therapeutic targets database (TTD) and Drugbank etc (2,3).”
The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis
Zhang, Q., Abdo, R., Iosef, C., Kaneko, T., Cecchini, M., Han, V. K., & Li, S. S.-C. (2022) · Nature Communications · doi:10.1038/s41467-022-33365-y · Cited by 197
Named Entity Recognition and Relation Detection for Biomedical Information Extraction
Perera, N., Dehmer, M., & Emmert-Streib, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00673 · Cited by 181
“…collections of jargon include Gene Ontology (Consortium, 2004), Chemical Entities of Biological Interest ( Shardlow et al., 2018), DrugBank (Wishart et al., 2017), Human Protein Reference Database (Keshava Prasad et al., 2008), Online Mendelian Inheritance in Man (Amberger et al., 2018),…”
BackgroundComputationally guided high-throughput design of self-assembling drug nanoparticles
Reker, D., Rybakova, Y., Kirtane, A. R., Cao, R., Yang, J. W., Navamajiti, N., Gardner, A., Zhang, R. M., Esfandiary, T., L’Heureux, J., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00870-y · Cited by 188
Deep learning for drug repurposing: Methods, databases, and applications
Pan, X., Lin, X., Cao, D., Zeng, X., Yu, P. S., He, L., Nussinov, R., & Cheng, F. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1597 · Cited by 188
“DrugBank[28] is a comprehensive database that combines detailed drug information with the corresponding drug targets.”
BackgroundArtificial intelligence to bring nanomedicine to life
Serov, N., & Vinogradov, V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114194 · Cited by 189
Generative Deep Learning for Targeted Compound Design
Sousa, T., Correia, J., Pereira, V., & Rocha, M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01496 · Cited by 191
Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y. (2023) · Pharmaceuticals · doi:10.3390/ph16091259 · Cited by 176
Sun, J., Zhao, J., Jiang, F., Wang, L., Xiao, Q., Han, F., Chen, J., Yuan, S., Wei, J., Larsson, S. C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01229-9 · Cited by 181
“…serve as potential therapeutic targets by searching the interactions between these proteins and drugs using DGIdb [36], ChEMBL [37], and DrugBank [38] databases, which prioritized the potential druggable targets by integrating information from drug-gene interactions, gene function, text mining,…”
BackgroundExpanding PROTACtable genome universe of E3 ligases
Liu, Y., Yang, J., Wang, T., Luo, M., Chen, Y., Chen, C., Ronai, Z., Zhou, Y., Ruppin, E., & Han, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42233-2 · Cited by 186
Self-citationKotlyar, M., Pastrello, C., Malik, Z., & Jurisica, I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1037 · Cited by 192
“PPIs were annotated with drugs that target either of the interacting proteins according to DrugBank (39) v5.”
MethodAn Overview of Machine Learning and Big Data for Drug Toxicity Evaluation
Vo, A. H., Van Vleet, T. R., Gupta, R. R., Liguori, M. J., & Rao, M. S. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00227 · Cited by 188
Cheng, L., Qi, C., Zhuang, H., Fu, T., & Zhang, X. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz843 · Cited by 192
The Methodological Trends of Traditional Herbal Medicine Employing Network Pharmacology
Lee, W.-Y., Lee, C.-Y., Kim, Y.-S., & Kim, C.-E. (2019) · Biomolecules · doi:10.3390/biom9080362 · Cited by 189
Kivits, T., Broers, H. P., Beeltje, H., van Vliet, M., & Griffioen, J. (2018) · Environmental Pollution · doi:10.1016/j.envpol.2018.05.085 · Cited by 182
“1: (Tolls, 2001), 2: (Hamscher, 2006), 3: (Sarmah et al., 2006), 4: (Banzhaf et al., 2012), 5: (García-Gal (cid:2) an et al., 2010), 6: (Zhang et al., 2014), 7: (Wishart et al., 2018), 8 (Rabølle and Spliid, 2000).”
Wu, Y., & Wang, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082358 · Cited by 193
Master Regulator Analysis of the SARS-CoV-2/Human Interactome
Guzzi, P. H., Mercatelli, D., Ceraolo, C., & Giorgi, F. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040982 · Cited by 193
“For example, a mild virus-activated protein in our network is the serine/threonine kinase MARK2 (Figure 1), which is one of the targets of the drug Fostamatinib in the treatment of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura [85].”
BackgroundFluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Sukhatme, V. P., Reiersen, A. M., Vayttaden, S. J., & Sukhatme, V. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652688 · Cited by 190
MatchMaker: A Deep Learning Framework for Drug Synergy Prediction
Kuru, H. I., Tastan, O., & Cicek, A. E. (2022) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3086702 · Cited by 186
IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus
Shao, S., Tsoi, L. C., Sarkar, M. K., Xing, X., Xue, K., Uppala, R., Berthier, C. C., Zeng, C., Patrick, M., Billi, A. C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7561 · Cited by 185
“D. S. Wishart, Y. D. Feunang, A. C. Guo, E. J. Lo, A. Marcu, J. R. Grant, T. Sajed, D. Johnson, C. Li, Z. Sayeeda, N. Assempour, I. Iynkkaran, Y. Liu, A. Maciejewski, N. Gale, A. Wilson, L. Chin, R. Cummings, D. Le, A. Pon, C. Knox, M. Wilson, DrugBank 5.0: A major update to the DrugBank database for 2018.”
InfluentialAutonomous, multiproperty-driven molecular discovery: From predictions to measurements and back
Koscher, B. A., Canty, R. B., McDonald, M. A., Greenman, K. P., McGill, C. J., Bilodeau, C. L., Jin, W., Wu, H., Vermeire, F. H., Jin, B., et al. (2023) · Science · doi:10.1126/science.adi1407 · Cited by 172
A probabilistic molecular fingerprint for big data settings
Probst, D., & Reymond, J.-L. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0321-8 · Cited by 186
Quantification for non-targeted LC/MS screening without standard substances
Liigand, J., Wang, T., Kellogg, J., Smedsgaard, J., Cech, N., & Kruve, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-62573-z · Cited by 183
Huanbutta, K., Burapapadh, K., Kraisit, P., Sriamornsak, P., Ganokratanaa, T., Suwanpitak, K., & Sangnim, T. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106938 · Cited by 231
Fischer, A., Sellner, M., Neranjan, S., Smieško, M., & Lill, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103626 · Cited by 165
“9 Antiviral approved **** a Ligand free binding energy predicted by MM/GBSA approach (excluding entropic contributions) with standard deviation; b Ligand efficiency determined from MM/GBSA score; c Pharmaceutical indication of the compound; d Indication and approval status derived from DrugBank [51]; e Quality of the…”
BackgroundMethodInfluentialEvaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 187
“Modality information was extracted from DrugBank and indication information from ATC codes, see Extended Data Table 1 for details. a) Forest plot of means (dots) and 95% confidence intervals of the mean (line segments) for gene sets evaluated for confounding with drug target status.”
A review on drug repurposing applicable to COVID-19
Dotolo, S., Marabotti, A., Facchiano, A., & Tagliaferri, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa288 · Cited by 181
“Some examples of general, freely available databases are ZINC [58], PubChem [59], DrugBank [ 60],Drug3D [61],SuperDRUG2 [62],ChEMBL [63],KEGG [64] and MTiOpenScreen [65].”
Background
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

